CA3239667A1 - Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp - Google Patents
Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp Download PDFInfo
- Publication number
- CA3239667A1 CA3239667A1 CA3239667A CA3239667A CA3239667A1 CA 3239667 A1 CA3239667 A1 CA 3239667A1 CA 3239667 A CA3239667 A CA 3239667A CA 3239667 A CA3239667 A CA 3239667A CA 3239667 A1 CA3239667 A1 CA 3239667A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285513P | 2021-12-03 | 2021-12-03 | |
| US63/285,513 | 2021-12-03 | ||
| EPPCT/EP2021/086689 | 2021-12-20 | ||
| PCT/EP2021/086689 WO2022136209A1 (en) | 2020-12-22 | 2021-12-20 | Interleukin 5 binding protein dosage regimen |
| US202263349622P | 2022-06-07 | 2022-06-07 | |
| US63/349,622 | 2022-06-07 | ||
| PCT/EP2022/084075 WO2023099668A1 (en) | 2021-12-03 | 2022-12-01 | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3239667A1 true CA3239667A1 (en) | 2023-06-08 |
Family
ID=84688427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3239667A Pending CA3239667A1 (en) | 2021-12-03 | 2022-12-01 | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250042985A1 (https=) |
| EP (1) | EP4440617A1 (https=) |
| JP (1) | JP2024542777A (https=) |
| CA (1) | CA3239667A1 (https=) |
| WO (1) | WO2023099668A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026047072A1 (en) * | 2024-08-30 | 2026-03-05 | Glaxosmithkline Intellectual Property Development Limited | Medical use |
| WO2026078117A1 (en) * | 2024-10-11 | 2026-04-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117018188A (zh) | 2017-05-26 | 2023-11-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 生物制药组合物和相关方法 |
-
2022
- 2022-12-01 CA CA3239667A patent/CA3239667A1/en active Pending
- 2022-12-01 JP JP2024532973A patent/JP2024542777A/ja active Pending
- 2022-12-01 WO PCT/EP2022/084075 patent/WO2023099668A1/en not_active Ceased
- 2022-12-01 US US18/715,320 patent/US20250042985A1/en active Pending
- 2022-12-01 EP EP22830693.2A patent/EP4440617A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024542777A (ja) | 2024-11-15 |
| EP4440617A1 (en) | 2024-10-09 |
| WO2023099668A1 (en) | 2023-06-08 |
| US20250042985A1 (en) | 2025-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12454571B2 (en) | Biopharmaceutical compositions | |
| JP2025106377A (ja) | Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること | |
| US11976113B2 (en) | Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins | |
| US20250042985A1 (en) | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp) | |
| US12286472B2 (en) | Biopharmaceutical compositions and methods for pediatric patients | |
| JP2021523881A (ja) | リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法 | |
| US20050089517A1 (en) | Treatment of respiratory diseases with anti-IL-2 receptor antibodies | |
| EP4267184B1 (en) | Interleukin 5 binding protein dosage regimen | |
| JP7798763B2 (ja) | Ｃ５関連疾患の治療または予防のための投与レジメン | |
| CN118524849A (zh) | 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案 | |
| JP2022549218A (ja) | 抗トリプターゼ抗体の投薬 | |
| WO2022136209A1 (en) | Interleukin 5 binding protein dosage regimen | |
| CN116635417A (zh) | 白介素5结合蛋白给药方案 | |
| WO2025238121A1 (en) | Anti-il-5 antibody in the treatment of asthma | |
| WO2025242619A1 (en) | Treatment for mucus plugging | |
| WO2026047072A1 (en) | Medical use | |
| WO2025221247A1 (en) | Treatment of eosinophilic esophagitis with anti-tslp antibody | |
| JP2026503045A (ja) | Ｔｓｌｐ抗体を使用して喘息を治療するための方法 | |
| CN121889429A (zh) | 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体 | |
| JP2023504679A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法 | |
| EA046656B1 (ru) | Антигенсвязывающие белки, которые связываются с il-5 и используются для лечения заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240704 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240926 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241126 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241126 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241126 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250422 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251119 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251119 |